xRead - An Update on Immunotherapy in Head and Neck Cancer (November 2025)
First page
Table of contents
Next page
Last page
Article 1 - Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
1
Article 2 - Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
16
Article 3 - Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma
28
Article 4 - Current Progress and Future Directions of Immunotherapy in Head and Neck Squamous Cell Carcinoma A Narrative Review
40
Article 5 - Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
48
Made with FlippingBook
flipbook maker